On CNBC's “Mad Money Lightning Round,” on Tuesday, Jim Cramer recommended buying Affirm Holdings, Inc. (NASDAQ:AFRM).Supporting his view, Rothschild & Co analyst Harry Bartlett, on Oct. 6, upgraded Affirm from Neutral to Buy and raised the price target from $74 to$101.“That's the speculative bottom there,” Cramer said when asked about Beam Therapeutics Inc. (NASDAQ:BEAM). “That one, I can't go with.”According to recent news, Beam Therapeutics announced on Aug. 14 that the FDA granted regenerative medicine ...